"Medidata is at the forefront of a critical shift in the life sciences sector," said Anthony Costello, CEO, Medidata. "By harnessing AI-powered solutions and partnering with visionaries, we aren't ...

Biogen and Eisai have already filed for approval of their ... condition that can cause problems with balance, movement, vision, speech and swallowing that also features a build-up of toxic tau ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

4307.T Nomura Research Institute, Ltd.

JSD has received institutional grant support from Eisai, UCB Pharma, GSK, Janssen Cilag, Medtronic, and GE Healthcare. AM has received support from UCB, Baxter, and Cyberonics. The remaining authors ...